HIGH AFFINITY HUMAN AND MONKEY SPECIFIC TFR-1 VNARS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Mar 27, 2025
app pub date -
Dec 11, 2024
filing date -
Dec 11, 2024
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to a high affinity, VNAR polypeptide cross reactive with primate transferrin receptors (“TfR”). This TfR-specific VNAR polypeptide was obtained by screening semisynthetic VNAR phage display libraries against recombinant human TfR-1. The VNAR polypeptides of the invention can be used alone or as a component in conjugates that target the transferrin/transferrin receptor transport system. The invention further includes use of this VNAR, its conjugates and other derivatives in diagnostic and therapeutic methods, e.g., to diagnose, treat and/or prevent a pathological condition, disorder or disease in which it is beneficial to deliver a heterologous biomolecule across the blood brain barrier or other membrane systems. This TfR-specific VNAR polypeptide can also be used to target other biological barriers such the intestines, the placenta or aberrant cells overexpressing TfR-1, for therapeutic benefit in treatment of certain cancer cells and tumors of various tissue types. Deimmunized VNAR scaffolds are also provided.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully